AD 32 lipophilic analog of anthracycline data

In Phase I results announced at the International Symposium of Urology in Portugal, 13 of 18 patients treated for papillary disease, a type of superficial bladder cancer, remained disease free after surgical removal of the tumor and prophylactic administration of AD 32. Of the 14 treated for carcinoma in situ, the other form of superficial bladder cancer, four have remained disease free, with two others responding temporarily. Twelve of these 14 patients had failed standard intra-bladder chemotherapies.

The trial showed no ill effects in nine of 32 patients, even at high doses, with virtually no systemic symptoms reported in the study. Most of the urinary adverse effects were low grade and transient bladder irritation, the company said. ...